HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer Meeting Abstract
| Authors: | Borad, M. J.; Shroff, R. T.; Abou-Alfa, G. K.; Hecht, J. R.; Bullock, A. J.; Ritch, P. S.; Chondros, D.; Muhsin, M.; Oh, D. Y. |
| Abstract Title: | HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer |
| Meeting Title: | 2018 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2018 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-01 |
| Language: | English |
| ACCESSION: | WOS:000436174100523 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2018.36.4_suppl.TPS543 |
| Notes: | Meeting Abstract: TPS543 -- Source: Wos |
